Gilead Sciences Inc.

NAS: GILD
Pharmaceuticals
Foster City CA
Title 1Executive Chairman
Executive 1Dr. John C. Martin, Ph.D., Executive Chairman | Executive Chairman
2015 Revenue (US$ Millions)$32,639
2014 Revenue (US$ Millions)$24,890
Revenue Growth (%)31.13%
Net Income (US$ Millions)$18,108
Common Shares Outstanding (Millions)$1,422
Earnings Per Share (US$)$11.91
Price To Earnings Ratio9.88
Total Equity (US$ Millions)$18,534
Return On Equity (%)117.39%
Long Term Debt (US$ Millions)$21,195
Debt To Equity Ratio (%)1.14%
Market Capitalization (US$ Millions)$143,892
Total Assets (US$ Millions)$51,839
Current Assets (US$ Millions)$24,763
Inventories (US$ Millions)$1,955
Current Liabilities (US$ Millions)$9,891
Cost of Goods Sold (US$ Millions)$4,006
Asset Turnover0.63
Inventory Turnover2.4